Surmodics, Inc.
Surmodics, Inc. (SRDX) Stock Competitors & Peer Comparison
See (SRDX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SRDX | $42.98 | +0.00% | 614.5M | -34.66 | -$1.24 | N/A |
| ABT | $114.51 | +2.07% | 195.3B | 30.16 | $3.72 | +2.13% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $383.18 | +2.82% | 145.5B | 45.15 | $8.42 | +0.89% |
| MDT | $98.36 | +0.79% | 124.3B | 26.47 | $3.66 | +2.92% |
| BSX | $74.61 | -1.47% | 110.6B | 38.43 | $1.94 | N/A |
| EW | $81.33 | +3.05% | 46.8B | 44.08 | $1.81 | N/A |
| BRKRP | $308.48 | +1.07% | 45.8B | N/A | N/A | +0.52% |
| PHG | $31.19 | +0.74% | 30B | 27.65 | $1.13 | +2.84% |
| DXCM | $74.09 | +2.51% | 28.5B | 34.97 | $2.09 | N/A |
Stock Comparison
SRDX vs ABT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ABT has a market cap of 195.3B. Regarding current trading prices, SRDX is priced at $42.98, while ABT trades at $114.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ABT's P/E ratio is 30.16. In terms of profitability, SRDX's ROE is -0.16%, compared to ABT's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ABT's competition here
SRDX vs BSX-PA Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, SRDX is priced at $42.98, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, SRDX's ROE is -0.16%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BSX-PA's competition here
SRDX vs SYK Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SYK has a market cap of 145.5B. Regarding current trading prices, SRDX is priced at $42.98, while SYK trades at $383.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SYK's P/E ratio is 45.15. In terms of profitability, SRDX's ROE is -0.16%, compared to SYK's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SYK's competition here
SRDX vs MDT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MDT has a market cap of 124.3B. Regarding current trading prices, SRDX is priced at $42.98, while MDT trades at $98.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MDT's P/E ratio is 26.47. In terms of profitability, SRDX's ROE is -0.16%, compared to MDT's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MDT's competition here
SRDX vs BSX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSX has a market cap of 110.6B. Regarding current trading prices, SRDX is priced at $42.98, while BSX trades at $74.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSX's P/E ratio is 38.43. In terms of profitability, SRDX's ROE is -0.16%, compared to BSX's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BSX's competition here
SRDX vs EW Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EW has a market cap of 46.8B. Regarding current trading prices, SRDX is priced at $42.98, while EW trades at $81.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EW's P/E ratio is 44.08. In terms of profitability, SRDX's ROE is -0.16%, compared to EW's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check EW's competition here
SRDX vs BRKRP Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BRKRP has a market cap of 45.8B. Regarding current trading prices, SRDX is priced at $42.98, while BRKRP trades at $308.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BRKRP's P/E ratio is N/A. In terms of profitability, SRDX's ROE is -0.16%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, SRDX is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BRKRP's competition here
SRDX vs PHG Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PHG has a market cap of 30B. Regarding current trading prices, SRDX is priced at $42.98, while PHG trades at $31.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PHG's P/E ratio is 27.65. In terms of profitability, SRDX's ROE is -0.16%, compared to PHG's ROE of +0.08%. Regarding short-term risk, SRDX is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PHG's competition here
SRDX vs DXCM Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, DXCM has a market cap of 28.5B. Regarding current trading prices, SRDX is priced at $42.98, while DXCM trades at $74.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas DXCM's P/E ratio is 34.97. In terms of profitability, SRDX's ROE is -0.16%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, SRDX is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check DXCM's competition here
SRDX vs STE Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, STE has a market cap of 24.6B. Regarding current trading prices, SRDX is priced at $42.98, while STE trades at $247.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas STE's P/E ratio is 34.92. In terms of profitability, SRDX's ROE is -0.16%, compared to STE's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check STE's competition here
SRDX vs ZBH Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ZBH has a market cap of 19.6B. Regarding current trading prices, SRDX is priced at $42.98, while ZBH trades at $98.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ZBH's P/E ratio is 27.82. In terms of profitability, SRDX's ROE is -0.16%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, SRDX is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ZBH's competition here
SRDX vs ABMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, SRDX is priced at $42.98, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ABMD's P/E ratio is 65.36. In terms of profitability, SRDX's ROE is -0.16%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ABMD's competition here
SRDX vs PODD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PODD has a market cap of 17B. Regarding current trading prices, SRDX is priced at $42.98, while PODD trades at $247.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PODD's P/E ratio is 70.32. In terms of profitability, SRDX's ROE is -0.16%, compared to PODD's ROE of +0.17%. Regarding short-term risk, SRDX is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PODD's competition here
SRDX vs SNN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SNN has a market cap of 15.8B. Regarding current trading prices, SRDX is priced at $42.98, while SNN trades at $36.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SNN's P/E ratio is 32.22. In terms of profitability, SRDX's ROE is -0.16%, compared to SNN's ROE of +0.09%. Regarding short-term risk, SRDX is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SNN's competition here
SRDX vs ALGN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, SRDX is priced at $42.98, while ALGN trades at $177.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ALGN's P/E ratio is 33.63. In terms of profitability, SRDX's ROE is -0.16%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ALGN's competition here
SRDX vs PEN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PEN has a market cap of 13.3B. Regarding current trading prices, SRDX is priced at $42.98, while PEN trades at $339.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PEN's P/E ratio is 80.98. In terms of profitability, SRDX's ROE is -0.16%, compared to PEN's ROE of +0.13%. Regarding short-term risk, SRDX is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PEN's competition here
SRDX vs SWAV Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, SRDX is priced at $42.98, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SWAV's P/E ratio is 78.76. In terms of profitability, SRDX's ROE is -0.16%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, SRDX is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SWAV's competition here
SRDX vs GMED Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GMED has a market cap of 12.1B. Regarding current trading prices, SRDX is priced at $42.98, while GMED trades at $92.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GMED's P/E ratio is 29.32. In terms of profitability, SRDX's ROE is -0.16%, compared to GMED's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check GMED's competition here
SRDX vs BIO Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BIO has a market cap of 7.3B. Regarding current trading prices, SRDX is priced at $42.98, while BIO trades at $269.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BIO's P/E ratio is 9.74. In terms of profitability, SRDX's ROE is -0.16%, compared to BIO's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BIO's competition here
SRDX vs BIO-B Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BIO-B has a market cap of 7.1B. Regarding current trading prices, SRDX is priced at $42.98, while BIO-B trades at $268.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BIO-B's P/E ratio is 9.40. In terms of profitability, SRDX's ROE is -0.16%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, SRDX is less volatile compared to BIO-B. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BIO-B's competition here
SRDX vs GKOS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, GKOS has a market cap of 6.9B. Regarding current trading prices, SRDX is priced at $42.98, while GKOS trades at $119.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas GKOS's P/E ratio is -80.81. In terms of profitability, SRDX's ROE is -0.16%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, SRDX is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check GKOS's competition here
SRDX vs BRKR Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, SRDX is priced at $42.98, while BRKR trades at $39.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BRKR's P/E ratio is -255.20. In terms of profitability, SRDX's ROE is -0.16%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, SRDX is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BRKR's competition here
SRDX vs IRTC Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IRTC has a market cap of 4.9B. Regarding current trading prices, SRDX is priced at $42.98, while IRTC trades at $143.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IRTC's P/E ratio is -93.19. In terms of profitability, SRDX's ROE is -0.16%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, SRDX is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check IRTC's competition here
SRDX vs NARI Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, SRDX is priced at $42.98, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NARI's P/E ratio is -59.24. In terms of profitability, SRDX's ROE is -0.16%, compared to NARI's ROE of -0.00%. Regarding short-term risk, SRDX is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NARI's competition here
SRDX vs TMDX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TMDX has a market cap of 4.6B. Regarding current trading prices, SRDX is priced at $42.98, while TMDX trades at $132.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TMDX's P/E ratio is 53.06. In terms of profitability, SRDX's ROE is -0.16%, compared to TMDX's ROE of +0.31%. Regarding short-term risk, SRDX is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TMDX's competition here
SRDX vs LIVN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LIVN has a market cap of 3.7B. Regarding current trading prices, SRDX is priced at $42.98, while LIVN trades at $67.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LIVN's P/E ratio is -17.19. In terms of profitability, SRDX's ROE is -0.16%, compared to LIVN's ROE of -0.19%. Regarding short-term risk, SRDX is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LIVN's competition here
SRDX vs AXNX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, SRDX is priced at $42.98, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AXNX's P/E ratio is -709.80. In terms of profitability, SRDX's ROE is -0.16%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, SRDX and AXNX have similar daily volatility (0.00).Check AXNX's competition here
SRDX vs ITGR Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, SRDX is priced at $42.98, while ITGR trades at $85.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ITGR's P/E ratio is 34.93. In terms of profitability, SRDX's ROE is -0.16%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, SRDX is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ITGR's competition here
SRDX vs ESTA Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, SRDX is priced at $42.98, while ESTA trades at $74.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ESTA's P/E ratio is -26.76. In terms of profitability, SRDX's ROE is -0.16%, compared to ESTA's ROE of -2.54%. Regarding short-term risk, SRDX is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ESTA's competition here
SRDX vs NUVA Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, SRDX is priced at $42.98, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NUVA's P/E ratio is 75.00. In terms of profitability, SRDX's ROE is -0.16%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NUVA's competition here
SRDX vs PMI Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PMI has a market cap of 2B. Regarding current trading prices, SRDX is priced at $42.98, while PMI trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PMI's P/E ratio is -2.84. In terms of profitability, SRDX's ROE is -0.16%, compared to PMI's ROE of +1.64%. Regarding short-term risk, SRDX is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PMI's competition here
SRDX vs ATEC Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, SRDX is priced at $42.98, while ATEC trades at $12.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ATEC's P/E ratio is -12.51. In terms of profitability, SRDX's ROE is -0.16%, compared to ATEC's ROE of -103.69%. Regarding short-term risk, SRDX is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ATEC's competition here
SRDX vs AORT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, SRDX is priced at $42.98, while AORT trades at $37.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AORT's P/E ratio is 182.64. In terms of profitability, SRDX's ROE is -0.16%, compared to AORT's ROE of +0.02%. Regarding short-term risk, SRDX is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AORT's competition here
SRDX vs UFPT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, SRDX is priced at $42.98, while UFPT trades at $239.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas UFPT's P/E ratio is 27.15. In terms of profitability, SRDX's ROE is -0.16%, compared to UFPT's ROE of +0.18%. Regarding short-term risk, SRDX is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check UFPT's competition here
SRDX vs AXGN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AXGN has a market cap of 1.8B. Regarding current trading prices, SRDX is priced at $42.98, while AXGN trades at $35.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AXGN's P/E ratio is -706.00. In terms of profitability, SRDX's ROE is -0.16%, compared to AXGN's ROE of -0.02%. Regarding short-term risk, SRDX is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AXGN's competition here
SRDX vs INSP Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, SRDX is priced at $42.98, while INSP trades at $58.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INSP's P/E ratio is 12.19. In terms of profitability, SRDX's ROE is -0.16%, compared to INSP's ROE of +0.21%. Regarding short-term risk, SRDX is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check INSP's competition here
SRDX vs TNDM Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TNDM has a market cap of 1.7B. Regarding current trading prices, SRDX is priced at $42.98, while TNDM trades at $28.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TNDM's P/E ratio is -8.11. In terms of profitability, SRDX's ROE is -0.16%, compared to TNDM's ROE of -1.20%. Regarding short-term risk, SRDX is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TNDM's competition here
SRDX vs PRCT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, SRDX is priced at $42.98, while PRCT trades at $27.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PRCT's P/E ratio is -17.82. In terms of profitability, SRDX's ROE is -0.16%, compared to PRCT's ROE of -0.22%. Regarding short-term risk, SRDX is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PRCT's competition here
SRDX vs AHCO Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, SRDX is priced at $42.98, while AHCO trades at $10.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AHCO's P/E ratio is 18.80. In terms of profitability, SRDX's ROE is -0.16%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AHCO's competition here
SRDX vs CNMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, SRDX is priced at $42.98, while CNMD trades at $45.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CNMD's P/E ratio is 29.90. In terms of profitability, SRDX's ROE is -0.16%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CNMD's competition here
SRDX vs LMRI Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LMRI has a market cap of 1.4B. Regarding current trading prices, SRDX is priced at $42.98, while LMRI trades at $15.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LMRI's P/E ratio is -31.63. In terms of profitability, SRDX's ROE is -0.16%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, SRDX is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LMRI's competition here
SRDX vs IRMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98, while IRMD trades at $100.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IRMD's P/E ratio is 59.18. In terms of profitability, SRDX's ROE is -0.16%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, SRDX is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check IRMD's competition here
SRDX vs HSKA Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, SRDX is priced at $42.98, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas HSKA's P/E ratio is -62.49. In terms of profitability, SRDX's ROE is -0.16%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, SRDX and HSKA have similar daily volatility (0.00).Check HSKA's competition here
SRDX vs SILK Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SILK's P/E ratio is -18.96. In terms of profitability, SRDX's ROE is -0.16%, compared to SILK's ROE of -0.35%. Regarding short-term risk, SRDX is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SILK's competition here
SRDX vs FNA Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, SRDX is priced at $42.98, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas FNA's P/E ratio is -19.83. In terms of profitability, SRDX's ROE is -0.16%, compared to FNA's ROE of -0.17%. Regarding short-term risk, SRDX is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check FNA's competition here
SRDX vs INMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INMD has a market cap of 964.3M. Regarding current trading prices, SRDX is priced at $42.98, while INMD trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INMD's P/E ratio is 10.21. In terms of profitability, SRDX's ROE is -0.16%, compared to INMD's ROE of +0.15%. Regarding short-term risk, SRDX is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check INMD's competition here
SRDX vs SSII Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SSII has a market cap of 959.4M. Regarding current trading prices, SRDX is priced at $42.98, while SSII trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SSII's P/E ratio is -82.58. In terms of profitability, SRDX's ROE is -0.16%, compared to SSII's ROE of -0.50%. Regarding short-term risk, SRDX is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SSII's competition here
SRDX vs IART Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, IART has a market cap of 951.1M. Regarding current trading prices, SRDX is priced at $42.98, while IART trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas IART's P/E ratio is -1.89. In terms of profitability, SRDX's ROE is -0.16%, compared to IART's ROE of -0.39%. Regarding short-term risk, SRDX is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check IART's competition here
SRDX vs CSII Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, SRDX is priced at $42.98, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CSII's P/E ratio is -20.83. In terms of profitability, SRDX's ROE is -0.16%, compared to CSII's ROE of -0.14%. Regarding short-term risk, SRDX is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CSII's competition here
SRDX vs BFLY Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BFLY has a market cap of 754M. Regarding current trading prices, SRDX is priced at $42.98, while BFLY trades at $2.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BFLY's P/E ratio is -9.05. In terms of profitability, SRDX's ROE is -0.16%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, SRDX is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BFLY's competition here
SRDX vs CBLL Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CBLL has a market cap of 750.1M. Regarding current trading prices, SRDX is priced at $42.98, while CBLL trades at $19.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CBLL's P/E ratio is -5.51. In terms of profitability, SRDX's ROE is -0.16%, compared to CBLL's ROE of -0.30%. Regarding short-term risk, SRDX is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CBLL's competition here
SRDX vs CRY Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, SRDX is priced at $42.98, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CRY's P/E ratio is 425.71. In terms of profitability, SRDX's ROE is -0.16%, compared to CRY's ROE of +0.02%. Regarding short-term risk, SRDX is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CRY's competition here
SRDX vs AVNS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AVNS has a market cap of 718.1M. Regarding current trading prices, SRDX is priced at $42.98, while AVNS trades at $15.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AVNS's P/E ratio is -1.52. In terms of profitability, SRDX's ROE is -0.16%, compared to AVNS's ROE of -0.58%. Regarding short-term risk, SRDX is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AVNS's competition here
SRDX vs SIBN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SIBN has a market cap of 671.7M. Regarding current trading prices, SRDX is priced at $42.98, while SIBN trades at $15.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SIBN's P/E ratio is -30.35. In terms of profitability, SRDX's ROE is -0.16%, compared to SIBN's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SIBN's competition here
SRDX vs TCMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TCMD has a market cap of 641.5M. Regarding current trading prices, SRDX is priced at $42.98, while TCMD trades at $28.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TCMD's P/E ratio is 44.18. In terms of profitability, SRDX's ROE is -0.16%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, SRDX is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TCMD's competition here
SRDX vs APEN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, SRDX is priced at $42.98, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas APEN's P/E ratio is -9.43. In terms of profitability, SRDX's ROE is -0.16%, compared to APEN's ROE of -0.85%. Regarding short-term risk, SRDX is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check APEN's competition here
SRDX vs BVS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BVS has a market cap of 574.7M. Regarding current trading prices, SRDX is priced at $42.98, while BVS trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BVS's P/E ratio is 53.63. In terms of profitability, SRDX's ROE is -0.16%, compared to BVS's ROE of +0.05%. Regarding short-term risk, SRDX is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BVS's competition here
SRDX vs VREX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, VREX has a market cap of 569.7M. Regarding current trading prices, SRDX is priced at $42.98, while VREX trades at $13.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas VREX's P/E ratio is -8.29. In terms of profitability, SRDX's ROE is -0.16%, compared to VREX's ROE of -0.14%. Regarding short-term risk, SRDX is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check VREX's competition here
SRDX vs CTKB Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CTKB has a market cap of 566.4M. Regarding current trading prices, SRDX is priced at $42.98, while CTKB trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CTKB's P/E ratio is -40.27. In terms of profitability, SRDX's ROE is -0.16%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, SRDX is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CTKB's competition here
SRDX vs OFIX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, OFIX has a market cap of 549.2M. Regarding current trading prices, SRDX is priced at $42.98, while OFIX trades at $13.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas OFIX's P/E ratio is -4.58. In terms of profitability, SRDX's ROE is -0.16%, compared to OFIX's ROE of -0.26%. Regarding short-term risk, SRDX is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check OFIX's competition here
SRDX vs ZIMV Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, SRDX is priced at $42.98, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, SRDX's ROE is -0.16%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, SRDX and ZIMV have similar daily volatility (0.00).Check ZIMV's competition here
SRDX vs BWAY Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BWAY has a market cap of 487.3M. Regarding current trading prices, SRDX is priced at $42.98, while BWAY trades at $23.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BWAY's P/E ratio is 83.17. In terms of profitability, SRDX's ROE is -0.16%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, SRDX is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BWAY's competition here
SRDX vs PACB Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PACB has a market cap of 486.1M. Regarding current trading prices, SRDX is priced at $42.98, while PACB trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PACB's P/E ratio is -0.88. In terms of profitability, SRDX's ROE is -0.16%, compared to PACB's ROE of -11.23%. Regarding short-term risk, SRDX is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PACB's competition here
SRDX vs NPCE Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NPCE has a market cap of 477.6M. Regarding current trading prices, SRDX is priced at $42.98, while NPCE trades at $14.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NPCE's P/E ratio is -19.12. In terms of profitability, SRDX's ROE is -0.16%, compared to NPCE's ROE of -1.37%. Regarding short-term risk, SRDX is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NPCE's competition here
SRDX vs CERS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CERS has a market cap of 462.9M. Regarding current trading prices, SRDX is priced at $42.98, while CERS trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CERS's P/E ratio is -30.12. In terms of profitability, SRDX's ROE is -0.16%, compared to CERS's ROE of -0.28%. Regarding short-term risk, SRDX is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CERS's competition here
SRDX vs LAB Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LAB has a market cap of 434.6M. Regarding current trading prices, SRDX is priced at $42.98, while LAB trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LAB's P/E ratio is -2.90. In terms of profitability, SRDX's ROE is -0.16%, compared to LAB's ROE of -0.29%. Regarding short-term risk, SRDX is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LAB's competition here
SRDX vs KIDS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, KIDS has a market cap of 425.3M. Regarding current trading prices, SRDX is priced at $42.98, while KIDS trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas KIDS's P/E ratio is -8.65. In terms of profitability, SRDX's ROE is -0.16%, compared to KIDS's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check KIDS's competition here
SRDX vs CATX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CATX has a market cap of 421.5M. Regarding current trading prices, SRDX is priced at $42.98, while CATX trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CATX's P/E ratio is -3.75. In terms of profitability, SRDX's ROE is -0.16%, compared to CATX's ROE of -0.39%. Regarding short-term risk, SRDX is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CATX's competition here
SRDX vs CLPT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CLPT has a market cap of 420.9M. Regarding current trading prices, SRDX is priced at $42.98, while CLPT trades at $14.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CLPT's P/E ratio is -17.05. In terms of profitability, SRDX's ROE is -0.16%, compared to CLPT's ROE of -1.14%. Regarding short-term risk, SRDX is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CLPT's competition here
SRDX vs RXST Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, RXST has a market cap of 354.8M. Regarding current trading prices, SRDX is priced at $42.98, while RXST trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas RXST's P/E ratio is -9.81. In terms of profitability, SRDX's ROE is -0.16%, compared to RXST's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check RXST's competition here
SRDX vs DCTH Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, DCTH has a market cap of 339.4M. Regarding current trading prices, SRDX is priced at $42.98, while DCTH trades at $9.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas DCTH's P/E ratio is 326.00. In terms of profitability, SRDX's ROE is -0.16%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, SRDX is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check DCTH's competition here
SRDX vs SENS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SENS has a market cap of 333.4M. Regarding current trading prices, SRDX is priced at $42.98, while SENS trades at $8.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SENS's P/E ratio is -5.30. In terms of profitability, SRDX's ROE is -0.16%, compared to SENS's ROE of -1.35%. Regarding short-term risk, SRDX is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SENS's competition here
SRDX vs VMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, VMD has a market cap of 319.6M. Regarding current trading prices, SRDX is priced at $42.98, while VMD trades at $8.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas VMD's P/E ratio is 24.24. In terms of profitability, SRDX's ROE is -0.16%, compared to VMD's ROE of +0.10%. Regarding short-term risk, SRDX is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check VMD's competition here
SRDX vs SMLR Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, SRDX is priced at $42.98, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SMLR's P/E ratio is 3.92. In terms of profitability, SRDX's ROE is -0.16%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, SRDX and SMLR have similar daily volatility (0.00).Check SMLR's competition here
SRDX vs SGHT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SGHT has a market cap of 285.5M. Regarding current trading prices, SRDX is priced at $42.98, while SGHT trades at $5.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SGHT's P/E ratio is -6.00. In terms of profitability, SRDX's ROE is -0.16%, compared to SGHT's ROE of -0.62%. Regarding short-term risk, SRDX is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SGHT's competition here
SRDX vs QTRX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QTRX has a market cap of 269.1M. Regarding current trading prices, SRDX is priced at $42.98, while QTRX trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QTRX's P/E ratio is -2.46. In terms of profitability, SRDX's ROE is -0.16%, compared to QTRX's ROE of -0.31%. Regarding short-term risk, SRDX is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check QTRX's competition here
SRDX vs MGRM Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, SRDX is priced at $42.98, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MGRM's P/E ratio is -11.11. In terms of profitability, SRDX's ROE is -0.16%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, SRDX and MGRM have similar daily volatility (0.00).Check MGRM's competition here
SRDX vs MASS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MASS has a market cap of 241.4M. Regarding current trading prices, SRDX is priced at $42.98, while MASS trades at $6.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MASS's P/E ratio is -3.22. In terms of profitability, SRDX's ROE is -0.16%, compared to MASS's ROE of -0.03%. Regarding short-term risk, SRDX is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MASS's competition here
SRDX vs NVRO Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, SRDX is priced at $42.98, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NVRO's P/E ratio is -1.91. In terms of profitability, SRDX's ROE is -0.16%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, SRDX is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NVRO's competition here
SRDX vs PROF Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, PROF has a market cap of 210.2M. Regarding current trading prices, SRDX is priced at $42.98, while PROF trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas PROF's P/E ratio is -5.27. In terms of profitability, SRDX's ROE is -0.16%, compared to PROF's ROE of -0.92%. Regarding short-term risk, SRDX is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check PROF's competition here
SRDX vs EYES Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, SRDX is priced at $42.98, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EYES's P/E ratio is N/A. In terms of profitability, SRDX's ROE is -0.16%, compared to EYES's ROE of -4.16%. Regarding short-term risk, SRDX is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check EYES's competition here
SRDX vs SNWV Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, SNWV has a market cap of 208M. Regarding current trading prices, SRDX is priced at $42.98, while SNWV trades at $24.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas SNWV's P/E ratio is -33.22. In terms of profitability, SRDX's ROE is -0.16%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, SRDX is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check SNWV's competition here
SRDX vs ELMD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ELMD has a market cap of 203.2M. Regarding current trading prices, SRDX is priced at $42.98, while ELMD trades at $25.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ELMD's P/E ratio is 23.65. In terms of profitability, SRDX's ROE is -0.16%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, SRDX is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ELMD's competition here
SRDX vs BSGM Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, SRDX is priced at $42.98, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas BSGM's P/E ratio is -5.81. In terms of profitability, SRDX's ROE is -0.16%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, SRDX is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check BSGM's competition here
SRDX vs AVR Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, AVR has a market cap of 186.9M. Regarding current trading prices, SRDX is priced at $42.98, while AVR trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas AVR's P/E ratio is -2.18. In terms of profitability, SRDX's ROE is -0.16%, compared to AVR's ROE of -2.51%. Regarding short-term risk, SRDX is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check AVR's competition here
SRDX vs OWLT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, OWLT has a market cap of 181.5M. Regarding current trading prices, SRDX is priced at $42.98, while OWLT trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas OWLT's P/E ratio is -4.04. In terms of profitability, SRDX's ROE is -0.16%, compared to OWLT's ROE of +1.27%. Regarding short-term risk, SRDX is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check OWLT's competition here
SRDX vs TLSI Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, TLSI has a market cap of 180.1M. Regarding current trading prices, SRDX is priced at $42.98, while TLSI trades at $5.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas TLSI's P/E ratio is -2.57. In terms of profitability, SRDX's ROE is -0.16%, compared to TLSI's ROE of +1.49%. Regarding short-term risk, SRDX is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check TLSI's competition here
SRDX vs MDGS Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, SRDX is priced at $42.98, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas MDGS's P/E ratio is -0.27. In terms of profitability, SRDX's ROE is -0.16%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, SRDX is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check MDGS's competition here
SRDX vs EDAP Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, EDAP has a market cap of 176.1M. Regarding current trading prices, SRDX is priced at $42.98, while EDAP trades at $4.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas EDAP's P/E ratio is -8.26. In terms of profitability, SRDX's ROE is -0.16%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, SRDX is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check EDAP's competition here
SRDX vs RPID Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, RPID has a market cap of 172.4M. Regarding current trading prices, SRDX is priced at $42.98, while RPID trades at $3.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas RPID's P/E ratio is -3.89. In terms of profitability, SRDX's ROE is -0.16%, compared to RPID's ROE of -0.74%. Regarding short-term risk, SRDX is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check RPID's competition here
SRDX vs CVRX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, CVRX has a market cap of 160.8M. Regarding current trading prices, SRDX is priced at $42.98, while CVRX trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas CVRX's P/E ratio is -3.00. In terms of profitability, SRDX's ROE is -0.16%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, SRDX is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check CVRX's competition here
SRDX vs QIPT Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QIPT has a market cap of 160.5M. Regarding current trading prices, SRDX is priced at $42.98, while QIPT trades at $3.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QIPT's P/E ratio is -15.70. In terms of profitability, SRDX's ROE is -0.16%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, SRDX is less volatile compared to QIPT. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check QIPT's competition here
SRDX vs INGN Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, INGN has a market cap of 157.2M. Regarding current trading prices, SRDX is priced at $42.98, while INGN trades at $5.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas INGN's P/E ratio is -5.79. In terms of profitability, SRDX's ROE is -0.16%, compared to INGN's ROE of -0.13%. Regarding short-term risk, SRDX is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check INGN's competition here
SRDX vs APYX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, APYX has a market cap of 155.1M. Regarding current trading prices, SRDX is priced at $42.98, while APYX trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas APYX's P/E ratio is -10.50. In terms of profitability, SRDX's ROE is -0.16%, compared to APYX's ROE of -1.54%. Regarding short-term risk, SRDX is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check APYX's competition here
SRDX vs NNOX Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, NNOX has a market cap of 154.9M. Regarding current trading prices, SRDX is priced at $42.98, while NNOX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas NNOX's P/E ratio is -2.76. In terms of profitability, SRDX's ROE is -0.16%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, SRDX is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check NNOX's competition here
SRDX vs ANIK Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, ANIK has a market cap of 153.3M. Regarding current trading prices, SRDX is priced at $42.98, while ANIK trades at $10.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas ANIK's P/E ratio is -10.74. In terms of profitability, SRDX's ROE is -0.16%, compared to ANIK's ROE of -0.22%. Regarding short-term risk, SRDX is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check ANIK's competition here
SRDX vs QTI Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, QTI has a market cap of 149.5M. Regarding current trading prices, SRDX is priced at $42.98, while QTI trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas QTI's P/E ratio is -2.28. In terms of profitability, SRDX's ROE is -0.16%, compared to QTI's ROE of +1.72%. Regarding short-term risk, SRDX is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check QTI's competition here
SRDX vs LNSR Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LNSR has a market cap of 139.6M. Regarding current trading prices, SRDX is priced at $42.98, while LNSR trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LNSR's P/E ratio is -2.68. In terms of profitability, SRDX's ROE is -0.16%, compared to LNSR's ROE of +5.33%. Regarding short-term risk, SRDX is less volatile compared to LNSR. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LNSR's competition here
SRDX vs LUCD Comparison February 2026
SRDX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SRDX stands at 614.5M. In comparison, LUCD has a market cap of 138.4M. Regarding current trading prices, SRDX is priced at $42.98, while LUCD trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SRDX currently has a P/E ratio of -34.66, whereas LUCD's P/E ratio is -1.77. In terms of profitability, SRDX's ROE is -0.16%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, SRDX is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for SRDX.Check LUCD's competition here